SRR10841996
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- MYC_TARGETS_V2+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- PANCREAS_BETA_CELLS+0.400
- ANGIOGENESIS+0.300
- DNA_REPAIR+0.300
- FATTY_ACID_METABOLISM+0.300
- MTORC1_SIGNALING+0.300
Top 10 suppressed
- TGF_BETA_SIGNALING-0.400
- WNT_BETA_CATENIN_SIGNALING-0.400
- HEDGEHOG_SIGNALING-0.300
- MYOGENESIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- IL2_STAT5_SIGNALING-0.200
- NOTCH_SIGNALING-0.200
- UV_RESPONSE_DN-0.200
- ESTROGEN_RESPONSE_EARLY-0.100
- HYPOXIA-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG767 | — | — | 0.844 |
| 2 | SRR11296765 | — | — | 0.807 |
| 3 | SRR6013495 | — | cohortA1 | 0.802 |
| 4 | SRR8518397 | — | E | 0.798 |
| 5 | TCGA-BH-A18U-01A-21R-A12D-07 | — | C | 0.790 |
| 6 | TCGA-18-3421-01A-01R-0980-07 | — | cohortSQ1 | 0.787 |
| 7 | d31b7542-ab53-4c4f-b070-0c50bb195d1c | — | — | 0.786 |
| 8 | 930630ee-1c36-4567-aeff-042eef1654e6 | — | — | 0.785 |
| 9 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.774 |
| 10 | BSR_12_0070_A1_S79 | — | C | 0.773 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |